tiprankstipranks
Advertisement
Advertisement
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISI
PremiumThe FlyJanux Therapeutics price target lowered to $22 from $23 at Evercore ISI
2M ago
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
Premium
Ratings
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
2M ago
Janux Therapeutics price target lowered to $36 from $45 at Wedbush
Premium
The Fly
Janux Therapeutics price target lowered to $36 from $45 at Wedbush
2M ago
Janux Therapeutics downgraded to Underweight from Overweight at Barclays
PremiumThe FlyJanux Therapeutics downgraded to Underweight from Overweight at Barclays
2M ago
Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
Premium
Ratings
Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
3M ago
Janux Therapeutics says first patient dosed in Phase 1 study of JANX014
Premium
The Fly
Janux Therapeutics says first patient dosed in Phase 1 study of JANX014
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100